Gosset AMPA-type glutamate receptor Overview
AMPA-type glutamate receptors are tetrameric ion channels in the central nervous system that mediate the majority of fast excitatory synaptic transmission[1][2][4][5]. Each receptor is assembled from four subunits (GluA1–GluA4, encoded by GRIA1–GRIA4), which combine to form ligand-gated cation channels permeable primarily to sodium and, depending on subunit composition, calcium[1][2][5]. Upon glutamate binding, these receptors open rapidly, causing depolarization of the postsynaptic neuron and enabling high-fidelity neuronal signaling[1][2]. Their function is tightly modulated by auxiliary subunits (such as TARPs and cornichons), alternative splicing, and RNA editing, factors that fine-tune synaptic strength and plasticity[3][4][5][6][7]. AMPAR dysfunction or dysregulation is implicated in a broad range of neurological and psychiatric diseases, including epilepsy, neurodegenerative disorders, stroke, and chronic pain[2][5]. Drugs that modulate AMPA-type glutamate receptors are clinically approved for indications like epilepsy and are in development for additional neuropsychiatric conditions[1].
Mechanism of Action
Noncompetitive antagonism (e.g., perampanel inhibits AMPAR-mediated signaling by binding allosterically); Competitive antagonism (e.g., NBQX blocks glutamate binding); Positive allosteric modulation (e.g., cyclothiazide prolongs channel opening)
Biological Functions
Disease Associations
Safety Considerations
- Central nervous system depression (due to excessive inhibition)
- Seizures (in cases of excessive activation or impaired desensitization)
- Cognitive impairment
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Differential expression of AMPA receptor subunits (e.g., GluA1, GluA2) in disease states |
| Post-translational modification patterns (e.g., phosphorylation of subunits) |